TCGA-OL-A66H-01A-11R-A29R-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 27
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.520
- MYC_TARGETS_V2+0.410
- ALLOGRAFT_REJECTION+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- IL6_JAK_STAT3_SIGNALING+0.280
- DNA_REPAIR+0.240
- XENOBIOTIC_METABOLISM+0.220
- INFLAMMATORY_RESPONSE+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.180
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.440
- MITOTIC_SPINDLE-0.370
- UV_RESPONSE_DN-0.360
- TGF_BETA_SIGNALING-0.340
- G2M_CHECKPOINT-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.320
- PROTEIN_SECRETION-0.310
- NOTCH_SIGNALING-0.280
- E2F_TARGETS-0.260
- APICAL_SURFACE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.820 |
| 2 | TCGA-66-2785-01A-01R-0851-07 | — | cohortA1 | 0.813 |
| 3 | fe769a85-08b2-4442-aa8f-2b587e49001d | — | — | 0.812 |
| 4 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.809 |
| 5 | SRR2016951 | — | — | 0.802 |
| 6 | TCGA-A2-A25D-01A-12R-A16F-07 | — | B | 0.800 |
| 7 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.800 |
| 8 | MNG930 | — | — | 0.797 |
| 9 | TCGA-55-8085-01A-11R-2241-07 | — | cohortA4 | 0.794 |
| 10 | SRR8392897 | — | cohortSQ2 | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.090 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |